NCT02854826 (SAFE) is a clinical trial of SAFE Care model of care in Frail Older Adutls, sponsored by Cedars-Sinai Medical Center.

Who is sponsoring NCT02854826?

NCT02854826 is sponsored by Cedars-Sinai Medical Center.

What drugs are being tested in NCT02854826?

Interventions in NCT02854826: SAFE Care model of care.

What condition does NCT02854826 study?

NCT02854826 studies Frail Older Adutls.

Is NCT02854826 still recruiting?

NCT02854826 is currently completed. Last updated 31 August 2018.

Last reviewed 2018-08-31 · How we verify

NCT02854826: SAFE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Systems Addressing Frail Elders (SAFE) Care Implementation

Completed Last updated 31 August 2018

What this trial tests

trial testing SAFE Care model of care in Frail Older Adutls in 330 participants. Completed in 27 July 2018.

Timeline

1 July 2016

Primary endpoint
27 July 2018

27 July 2018

Quick facts

Lead sponsor	Cedars-Sinai Medical Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	330
Start date	1 July 2016
Primary completion	27 July 2018
Estimated completion	27 July 2018

Drugs / interventions tested

SAFE Care model of care

Conditions studied

Frail Older Adutls — all drugs for Frail Older Adutls →

Sponsor

Cedars-Sinai Medical Center

Who can join

Adults 18 to 110, any sex, with Frail Older Adutls. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Systems Addressing Frail Elders (SAFE) Care is a nurse-led interprofessional team model to rapidly identify and provide safe and effective inpatient care to high risk older adults and help support their successful transition back to the community. Developed and demonstrated to be effective in one hospital - the model is now being disseminated and studied in three additional hospitals (multiple organizational case study).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

NCT06012487 — Correlates and Control of Blood Pressure Variability · Phase 1 · not yet recruiting
NCT07495995 — SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis · Phase 2 · not yet recruiting
NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis · NA · not yet recruiting
NCT06521021 — CHOICE to AVOID or RESIST · NA · not yet recruiting
NCT07499089 — Together-Breast Cancer Support Platform · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02854826 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cedars-Sinai Medical Center
Last refreshed: 31 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02854826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing